Merck & Co.’s RSV Antibody Approved In US In Time To Compete With Blockbuster Beyfortus

CDC Sign-Off Expected In June, Orders To Follow In July

 
• By Mandy Jackson
  
Both Enflonsia and Beyfortus likely will be available for infants during the 2025-2026 RSV season in the US (Shutterstock)

More from Strategy

More from Scrip